Novo Nordisk’s blockbuster diabetes drug Ozempic (semaglutide) has already made the Danish drugmaker billions of dollars, and the company is aiming to capitalize on that success by expanding into higher doses and other indications like obesity and NASH. But late Monday the FDA told Novo:
Saudi Arabia’s plans for twin 100-mile-long skyscrapers have lost momentum amid spiraling costs and construction glitches.
In the bid to lock up patent rights to a growing suite of gene-editing technologies, Arbor Biotechnologies has acquired a small startup founded by MIT…
In the midst of the Covid-19 pandemic, while most scientists were busy plotting new ways to combat viruses, one startup quietly began a counterintuitive campaign:…
Novartis will pay $1 billion upfront to acquire radiopharmaceutical startup Mariana Oncology, just eight months after the preclinical biotech company disclosed a $175 million Series…
Reports first quarter revenues of $167 million, GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07) Prepares for launches of RSV vaccine…
Novartis is looking to build on its radiopharma research machinery. The maker of Lutathera and Pluvicto has expanded its long-standing peptide discovery deal with PeptiDream…
Japanese drugmaker Ono Pharmaceutical is acquiring cancer-focused biotech Deciphera Pharmaceuticals for $2.4 billion, the companies announced Monday morning. The deal will see Ono acquire all…
Other longevity researchers have rebuked the Harvard geneticist. “The selling is a step too far,” said one.
Other longevity researchers have rebuked the Harvard geneticist. “The selling is a step too far,” said one.
